From Yahoo Finance · · 50s
Revolution Medicines' Pancreatic Cancer Drug Shows Breakthrough Results
Revolution Medicines' new pancreatic cancer drug shows strong clinical results, signaling potential shift in cancer treatment approaches
In brief
Revolution Medicines' new pancreatic cancer drug shows strong clinical results, signaling potential shift in cancer treatment approaches Revolution Medicines' daraxonrasib drug candidate shows promise for pancreatic cancer treatment with potential to become new standard of care Originally reported by Yahoo Finance.
New Drug Candidate Results
Revolution Medicines' daraxonrasib drug candidate shows strong late-stage clinical results for pancreatic cancer
“In the Health Care sector, we see compelling long-term idiosyncratic growth opportunities in drug discovery, diagnostics and medical innovation”
Investor Letter Highlight
Parnassus Growth Equity Fund added Revolution Medicines to its Q2 2026 portfolio with strong growth potential
“During the quarter, we added Revolution Medicines, Inc. developer of a promising new drug for pancreatic cancer”
Market Performance
Revolution Medicines shares rose 358% over 52 weeks with $43.91 billion market cap
FDA Approval
FDA approved Revolution Medicines' Rasonque for metastatic pancreatic cancer treatment
Investor Outlook
Parnassus Growth Equity Fund sees strong long-term potential in Revolution Medicines' drug development
“Revolution Medicines' lead drug candidate, daraxonrasib, has delivered strong late-stage clinical results in pancreatic cancer”
The one thing
Revolution Medicines' daraxonrasib drug candidate shows promise for pancreatic cancer treatment with potential to become new standard of care
